TG Therapeutics (TGTX) Q1 FY26 earnings call

TG Therapeutics reported record Q1 FY26 revenue for BRIUMVI, driven by strong new patient enrollments and better-than-expected persistence, leading to a significant raise in full-year guidance. Strategic pipeline advancements for a simplified IV dosing and a subcutaneous formulation are underway, aiming to expand market reach and long-term value. The company also continues to deploy capital through share repurchases and disciplined business development.